Objectives: Fluoroquinolones are used in second-line treatment of tuberculosis (TB) and have a potential role in shortening TB treatment duration. The wide use of fluoroquinolones in the treatment of other infections, including respiratory tract infections in patients with (undiagnosed) active TB, could result in fluoroquinolone-resistant Mycobacterium tuberculosis. We determined the rate of fluoroquinolone resistance in M. tuberculosis isolates obtained from Tanzanian patients and linked this to previous fluoroquinolone exposure and mycobacterial resistance to rifampicin and isoniazid.
Introduction
Fluoroquinolones, a class of broad-spectrum antibacterial drugs, are pivotal second-line drugs in the treatment of multidrug-resistant (MDR) tuberculosis (TB) and are used as substitute agents in patients who are intolerant to the first-line TB drugs. 1, 2 Moreover, in vitro and in vivo experiments have shown that the newer fluoroquinolones moxifloxacin and gatifloxacin have the potential to shorten TB treatment duration, an important strategy in the fight against TB. 3 -6 The agents are currently being tested in Phase III clinical trials for their role in TB treatment regimens of shorter duration. 7 A potential problem with using fluoroquinolones in first-line TB treatment is that they are prescribed for treatment of a wide variety of bacterial infections, including empirical treatment of community-acquired pneumonia. 8, 9 Exposure to fluoroquinolone monotherapy in patients with as yet undiagnosed active TB can result in the emergence of fluoroquinolone-resistant Mycobacterium tuberculosis, and this could jeopardize the application of the fluoroquinolones in TB treatment regimens, particularly in regimens of shorter duration. 10, 11 Fluoroquinolone resistance in M. tuberculosis has been observed in a number of studies around the world, with resistance rates ranging from ,1% to .35%. 12 -15 In several studies, M. tuberculosis resistance to fluoroquinolones was associated with MDR TB (resistance to at least rifampicin and isoniazid), 16 -20 probably as a consequence of adding a fluoroquinolone to a failing multidrug TB treatment regimen. 11 In a number of studies, the association between previous fluoroquinolone use for any kind of infection and the development of fluoroquinolone resistance in patients with active TB was assessed. While the association was confirmed in some studies, 14, 21 other studies yielded more ambiguous results with respect to the existence of such a correlation 16, 19, 22 or showed a risk increment of fluoroquinolone resistance development only after substantial (i.e. .10 days) exposure to these drugs. 23 The occurrence of fluoroquinolone resistance in M. tuberculosis and its possible association with previous fluoroquinolone exposure has not yet been studied in Tanzania, one of the 22 countries with the highest burden of TB. 24 In a previous study, we assessed the extent of fluoroquinolone use for all kinds of infections in outpatients from the Kilimanjaro Region in northern Tanzania. We confirmed that the fluoroquinolones are widely used in Tanzania; they account for 12% of the total sales of antibacterial drugs in authorized pharmacies and are readily available in unauthorized drug outlets as well. 25 In the present study, we determined the occurrence of fluoroquinolone resistance in M. tuberculosis isolates from TB patients in the Kilimanjaro Region and we linked this to previous fluoroquinolone exposure and resistance to isoniazid and rifampicin.
Methods

Setting
The study was conducted in the Tanzanian Kilimanjaro Region, where the annual TB case notification rate (new and re-treatment cases) is around 178 per 100000 population. 25 Forty-one percent of TB patients in the region are diagnosed with smear-positive pulmonary TB and 59% with smear-negative pulmonary or extrapulmonary TB. Thirty-one percent of TB patients are co-infected with HIV. 26, 27 TB diagnosis is primarily based on clinical symptoms and Ziehl-Neelsen (ZN) smear microscopy for the detection of acid-fast bacilli (AFB), complemented by radiology in the case of AFB-negative smears. At the time this study was conducted, no TB culture facilities were available for routine practice in the Kilimanjaro Region, and there was no second-line treatment for drug-resistant TB. 28 
Study population and procedures
We conducted a cross-sectional study between April 2009 and June 2010 in patients who were diagnosed with smear-positive pulmonary TB and had not yet started TB treatment. Smear-positivity was defined as at least one AFB-positive smear out of two sputum samples; one spot and one morning sample. 28 District TB and Leprosy Coordinators from all seven districts of the Kilimanjaro Region were responsible for enrolling patients from their district's clinics. Because of logistical constraints (in particular, long travel times from the most distant districts to the culture laboratory), convenience sampling was applied, meaning that as many patients as logistically possible were enrolled.
Demographic and clinical data such as TB classification (new or re-treatment case) and HIV status were collected from medical files. A new TB case was defined as a patient who had not received more than 1 month of TB treatment in the past. Re-treatment cases included patients classified as treatment failures, returning after default and relapse cases. Trained clinicians interviewed patients on the use of antibacterial drugs with or without prescription in the previous 6 months (a longer period was expected to result in substantial recall bias) and explicitly asked about ciprofloxacin use (the fluoroquinolone that is most frequently used in Tanzania). 25 Furthermore, medical files were checked for fluoroquinolone prescriptions in the previous 6 months.
One spot sputum sample for culture and drug susceptibility testing to isoniazid, rifampicin, ciprofloxacin and moxifloxacin was collected from every patient. Ciprofloxacin was selected because this fluoroquinolone is sold most extensively in Tanzania, 25 and moxifloxacin was chosen because this is one of the newer fluoroquinolones with the potential to shorten TB treatment duration. 6 The study protocol was approved by the Institutional Review Board of the Kilimanjaro Christian Medical Centre (KCMC; Moshi, Tanzania) and the National Institute for Medical Research (Dar es Salaam, Tanzania). Written informed consent was obtained from all participants.
Laboratory analysis
After collection, sputum samples were refrigerated for a maximum of 1 week and transported to the TB culture laboratory of the KCMC. After decontamination, sputum samples were incubated in an automated liquid culture system (BACTEC MGIT960; BD Biosciences, Erembodegem, Belgium). The content of positive MGIT tubes was inoculated on blood agar plates for 24 h to assess possible contamination, and ZN microscopy was performed to confirm the presence of AFB. In the case of AFB positivity and growth on the blood agar plates, MGIT tube sediments underwent renewed decontamination and incubation. In the case of AFB positivity and no growth on the blood agar plates, concentrated MGIT tube sediments were subcultured on Lö wenstein -Jensen (LJ) slopes. Growth on LJ slopes was assessed after 8 weeks of incubation and the isolates obtained in this way were stored in glycerol at 2808C until transport to the National Tuberculosis Reference Laboratory of the National Institute for Public Health and the Environment (RIVM) in the Netherlands.
At the RIVM, the isolates were first identified as M. tuberculosis complex by spoligotyping. 29 Drug susceptibility testing was performed using BACTEC MGIT960; the drugs included in the panel and their critical concentrations were: isoniazid, 0.1 mg/L; rifampicin, 1 mg/L; ciprofloxacin, 1 mg/L; and moxifloxacin, 0.5 mg/L. 30 The process was controlled using EpiCenter software (Pasadena, CA, USA); standard MGIT960 conditions applied. Cultures were incubated for an additional 3 days after full appearance of the growth control. If growth was detected in a fluoroquinolonecontaining tube after the additional 3 days of incubation, but not before, the isolate was labelled 'intermediately resistant'. 31 All fluoroquinolone-resistant isolates were subjected to gyrA gene mutation analysis using the GenoType MTBDRsl reverse line blot assay (Hain Lifescience, Nehren, Germany). 30 The results were discussed with the District TB and Leprosy Coordinators and laboratory technicians to provide them with feedback on the quality of ZN microscopy in the region.
Results
Patient characteristics
A total of 379 sputum samples were collected. M. tuberculosis isolates were obtained from 291 of these 379 sputum samples. Thirty samples were culture-negative, 35 showed growth, but no M. tuberculosis, and 23 were contaminated.
The characteristics of the 291 patients with culture-confirmed TB are shown in Table 1 . Twenty-two (8%) of the 291 patients Low fluoroquinolone resistance in Mycobacterium tuberculosis from Tanzania 1811 JAC had a history of fluoroquinolone use in the previous 6 months; 11 (50%) had used the drug for respiratory symptoms and the others for gastrointestinal problems. Seven patients had used fluoroquinolones in the past month and 15 patients between 1 and 3 months ago. The median duration of fluoroquinolone use was 7 days (interquartile range: 5 -10 days); the maximum duration was 10 days. None of the patients had used the fluoroquinolones more than once in the previous 6 months.
Drug susceptibility test results
Isoniazid resistance was found in 26 M. tuberculosis isolates (8.9%), 3 of which were resistant to rifampicin as well, giving an MDR rate of 1.0%. Mono-resistance to rifampicin occurred in one isolate (0.3%). Ciprofloxacin resistance was found in two isolates (0.7%); one was intermediately resistant to ciprofloxacin and susceptible to moxifloxacin, and the other was resistant to ciprofloxacin and intermediately resistant to moxifloxacin. Both were susceptible to isoniazid and rifampicin. The isolate resistant to ciprofloxacin and intermediately resistant to moxifloxacin harboured an A90V mutation in the gyrA gene, but wild-type sequences were detected simultaneously. In the isolate intermediately resistant to ciprofloxacin and susceptible to moxifloxacin, no gyrA mutations were found.
The characteristics of the patients from whom resistant M. tuberculosis isolates were obtained are shown in Table 1 . The two patients with ciprofloxacin-resistant M. tuberculosis had no history of previous fluoroquinolone use and had not been treated for TB before. The patient from whom the M. tuberculosis isolate with intermediate resistance to ciprofloxacin was obtained was a 40-year-old HIV-positive woman with a CD4 count of 3 cells/mm 3 . The other patient was a 20-year-old HIVnegative man with a CD4 count of 478 cells/mm 3 . There was no known link between these two patients.
Discussion
Fluoroquinolone resistance in M. tuberculosis is uncommon in Tanzania, despite the widespread use of these antibacterial drugs in the treatment of bacterial infections. The proportion of M. tuberculosis isolates with fluoroquinolone resistance was less than 1% in our study population and there was no association with previous fluoroquinolone exposure in the two isolates with fluoroquinolone resistance. Both fluoroquinolone-resistant isolates were susceptible to rifampicin and isoniazid.
Fluoroquinolone resistance in M. tuberculosis is associated with mutations in the gyrA and, to a lesser extent, gyrB genes of the mycobacterial genome, but these mutations are not always present in resistant isolates. 11, 32 Cross-resistance between the different fluoroquinolones is common in M. tuberculosis. 33 It is hypothesized that resistance to fluoroquinolones with strong bactericidal activity against M. tuberculosis (such as moxifloxacin) is generated through a stepwise process of additive mutations, whereas resistance to ciprofloxacin and ofloxacin requires a single mutation only. 11 This could explain why the M. tuberculosis isolate with intermediate resistance to ciprofloxacin in our study was susceptible to moxifloxacin (and did not have mutations in gyrA) and why the isolate with resistance to ciprofloxacin was intermediately resistant to moxifloxacin. We found an A90V gyrA mutation in the latter isolate, but wild-type sequences were also detected, suggesting a single strain with both wild-type and mutant bacterial populations, as previously observed, 30 or a mixed infection with two strains. 30 Considering that our aim was to determine the rate of fluoroquinolone resistance in northern Tanzania and relate this to previous fluoroquinolone use, we decided to categorize the M. tuberculosis isolate with intermediate resistance to ciprofloxacin as fluoroquinolone resistant. However, the clinical relevance of intermediate fluoroquinolone resistance in M. tuberculosis remains controversial. 31 Low fluoroquinolone resistance rates were also found in two other studies from the African continent. 12, 14 In Tunisia, 0.8% fluoroquinolone resistance was found in a hospital-based study, but the association of fluoroquinolone resistance in M. tuberculosis with previous fluoroquinolone exposure was not investigated. 12 In Rwanda, the fluoroquinolone resistance rate was 0.6% in a nationwide study. The four patients with fluoroquinolone-resistant M. tuberculosis in this study all had a history of previous fluoroquinolone use (three as part of a second-line TB treatment regimen). 14 There are a few possible explanations for the low fluoroquinolone resistance rate and the absence of an obvious association with previous fluoroquinolone exposure in our study. As Devasia et al. 23 showed, the risk of fluoroquinolone resistance in M. tuberculosis isolates increases particularly after fluoroquinolone exposure of more than 10 days. In our patient population, Of the 29 re-treatment cases, 2 were defaulters who returned and 27 were classified as relapse cases. The two patients who returned after default both had pan-susceptible M. tuberculosis isolates.
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fluoroquinolone use was restricted to brief treatment episodes (5 -10 days) only. Moreover, at the time this study was conducted, there was no second-line treatment for MDR TB available and thus there was no risk of long-term fluoroquinolone exposure as part of a failing second-line TB treatment regimen in M. tuberculosis. In most regions where high (i.e. .15%) fluoroquinolone resistance rates in M. tuberculosis were observed, the occurrence of fluoroquinolone resistance was associated with resistance to rifampicin and isoniazid. 15, 20, 22, 34, 35 In our study, the rates of isoniazid, rifampicin, and isoniazid plus rifampicin (MDR) resistance were low: 8.9%, 0.3% and 1.0%, respectively, and comparable low rates of MDR TB were found in other studies from Tanzania. 27, 36 This study has some limitations. Since the prescription and sale of antibacterial drugs to patients in Tanzania is not automatically registered, it was difficult to obtain reliable information about previous fluoroquinolone use. Furthermore, it is unknown how long it takes for M. tuberculosis to develop fluoroquinolone resistance after fluoroquinolone exposure. Devasia et al. 23 assessed fluoroquinolone exposure over a period of 12 months prior to TB diagnosis and found that exposure that had occurred more than 60 days before TB diagnosis was associated with the highest risk of fluoroquinolone resistance. 23 We assessed fluoroquinolone use over a period of 6 months (180 days) prior to TB diagnosis only, because we expected that fluoroquinolone use longer than 6 months ago would be difficult for patients to recall.
In conclusion, our findings indicate that the occurrence of fluoroquinolone resistance in M. tuberculosis isolates obtained from Tanzanian patients is limited and not related to previous, brief episodes of fluoroquinolone exposure. This is an encouraging finding in light of the possible incorporation of the fluoroquinolones in first-line TB treatment regimens.
